The 20 Drug Brands AI Talks About Most (And What It Gets Wrong)
Ask ChatGPT about a drug interaction at 11pm and you get an answer in four seconds. No waiting room, no […]
The Drugs AI Talks About Most (And the Blind Spot No One’s Watching)
Ask ChatGPT what to take for Type 2 diabetes and there’s a good chance it says Ozempic before it says
The Call Before the Call: What AI Monitoring Tells Field Sales Teams Before the Rep Walks In
About two-thirds of practicing US physicians, roughly 650,000 people, now use a chatbot called OpenEvidence to help decide how to
Tapering Myths: The Withdrawal-Risk Stuff Everyone Thinks They Know (But Often Doesn’t)
There’s a particular kind of anxious logic that shows up whenever someone misses a dose, runs out of a prescription,
What Is AI Telling Patients About Your Drug? A Practical Guide to Monitoring ChatGPT, Claude, and Gemini
A working guide for Medical Affairs, Regulatory Affairs, Pharmacovigilance, and brand teams The short answer: Patients and physicians are already
Monitoring what AI is telling patients and prescribers about your drugs: A practical guide for Medical Affairs, Regulatory Affairs, Pharmacovigilance, and Brand teams
ChatGPT, Claude, and Gemini now field millions of medication questions a day. Here’s how pharma teams build a defensible, ongoing
The Biggest “Supplements Don’t Count” Drug-Interaction Errors—and the One Prescription Assumption Everyone Repeats
There’s a comforting myth in the drug marketplace: that the only interactions worth worrying about are between prescriptions, and that
The Brand-Switch Traps: Why “Same Drug” Still Isn’t the Same Deal
Drug switching is supposed to be boring—just swap one formulation for another and keep going. But if you’ve ever watched
From “Same Drug” to “Different Bottle”: The Brand-vs-Generic Substitution Questions That Keep Coming Back
Generic substitution shouldn’t be a guessing game. And yet—here we are. Every so often, a reader calls in with the
When Your Fastest-Growing Market Exists Outside the Label
How semaglutide and tirzepatide built a combined obesity-and-diabetes franchise worth tens of billions of dollars largely on off-label and compounded
Patients Don’t Skip Pills—Life Skips Them: the Online Questions Behind Drug-Use Friction
If you’ve ever watched a prescription sit on the counter while real life did what it does—work schedules, side effects,
The Label Says “X”: The Patient Hears “Y” (and Everyone Pays for the Misread)
There’s a special kind of quiet chaos that happens when a medicine label is misread. It’s rarely malicious. More often
